Galderma Laboratories LP v. Perrigo UK Finco Limited Partnership
3:17-cv-01860
Overview
Parties
Defendant
Perrigo UK Finco Limited Partnership NPE (University / Research)
Represented By
0 Attorneys ListedPlaintiff
Nestle Skin Health SA Operating Company
Represented By
5 Attorneys ListedMunck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Galderma SA NPE (Individual / Inventor)
Represented By
5 Attorneys ListedMunck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Counter Claimant
Perrigo Israel Pharmaceuticals Ltd Operating Company
Represented By
0 Attorneys ListedCounter Defendant
Galderma Laboratories LP NPE (Individual / Inventor)
Represented By
5 Attorneys ListedMunck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Court & Judges
Court
District Court, N.D. Texas (txnd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 14 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇫🇷 France | France Counterpart | View Official Patent → | |
| 🇫🇷 France | France Counterpart | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8815816
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
|
Filed: 2013-10-25
Issued: 2014-08-26
|
Active (6.9 yrs remaining)
Expires: 2033-10-25
|
|
|
US9089587
Treatment of papulopustular rosacea with ivermectin
|
Filed: 2014-04-21
Issued: 2015-07-28
|
Active (7.4 yrs remaining)
Expires: 2034-04-21
|
|
|
US9233117
Treatment of inflammatory lesions of rosacea with ivermectin
|
Filed: 2014-03-13
Issued: 2016-01-12
|
Active (7.3 yrs remaining)
Expires: 2034-03-13
|
|
|
US9233118
Treatment of papulopustular rosacea with ivermectin
|
Filed: 2014-03-13
Issued: 2016-01-12
|
Active (7.3 yrs remaining)
Expires: 2034-03-13
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).